

January 17, 2024  
J-Pharma Co., Ltd.

## Announcement of presentation at the J.P. Morgan Healthcare Conference 2025

J-Pharma Co., Ltd. (Headquarters: Yokohama, Kanagawa Prefecture, President & CEO: Masuhiro Yoshitake) is pleased to announce that Mr. Yutaka Fujimoto, Director and Chief Financial Officer (CFO) of J-Pharma, made a presentation at the 43rd J.P. Morgan Healthcare Conference held from January 13 to January 16, 2025.



J-Pharma is moving forward with plans to initiate a global Phase 3 study of our lead compound, *nanvuranlat*, for the second-line treatment of biliary tract cancer in 2025.

J-Pharma also plans to initiate three other clinical trials in 2025 to demonstrate the transformative potential of LAT1 inhibitors. In this presentation, we discussed the aims and progress of these clinical programs.

Only a few unlisted Japanese biotech ventures are selected to present at this conference every year. J-Pharma is honored to be presenting for five consecutive years.

1. Date and Time: Wednesday January 16, 2025 10:00 – 10:25 (U.S. Pacific Time)
2. Venue: San Francisco, California, U.S.A.
3. Presenter: Mr. Yutaka Fujimoto, Director & CFO

### **[For further information, please contact.]**

J-Pharma Co., Ltd.,  
Administration Department, Public Relations  
TEL: 045-506-1155  
FAX: 045-506-1156  
Mail: [info@j-pharma.com](mailto:info@j-pharma.com)